Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 15, 2006. The report serves as a notification to the market regarding voting rights and capital structure in conformity with the Transparency Directive's transitional provision 6.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a corporate governance notification regarding share capital and does not contain financial performance data.
Material Changes
The filing details the composition of GSK's issued share capital as of the reporting date:
- Total issued ordinary shares with voting rights: 5,991,369,750
- Ordinary shares held in Treasury: 232,697,678
- Total number of voting rights: 5,758,672,072
The total voting rights figure is designated for use by shareholders to calculate notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of voting rights (5,758,672,072) against the company's latest annual report to ensure accurate calculation of disclosure thresholds.
- Confirm the number of shares held in Treasury (232,697,678) to understand the difference between issued capital and voting capital.
- Review the company's Form 20-F for comprehensive financial metrics, as this Form 6-K contains no financial performance data.